Investors

Investors

CannPal Animal Therapeutics Limited (“CannPal”) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. The Company listed on the Australian Stock Exchange (ASX) in 2017, trading under the ASX ticker “CP1”. CannPal was founded to research, develop and commercialise, regulatory approved medicines derived from the medical cannabis plant to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and animal health markets by developing innovative therapeutics using cannabinoids. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

For media inquiries, please email julia@thecapitalnetwork.com.au

For general inquiries, please email info@cannpal.com or contact us.

Directors

Geoff StarrNon-Executive Chairman
Layton MillsManaging Director
Max JohnstonNon-Executive Director
Robert CliffordNon-Executive Director
Dr Kate AdamsNon-Executive Director

Company Secretary

Baden Bowen

Corporate Inquiries

Justin Klintberg
Merchant Corporate Advisory
E: Info@merchantgroup.com.au

Media enquiries

Julia Maguire
The Capital Network
M: +61 (0)419 815 386
E: julia@thecapitalnetwork.com.au

Registered Office

Level 3
45A Bay Street
Double Bay NSW 2028

Telephone: +61 (02) 6108 3622
Email: info@cannpal.com
Website: www.cannpal.com

Share Registry

Computershare Investor Services Pty Limited
Level 11
172 St Georges Terrace
Perth WA 6000

ASX Code

CP1

Solicitors

Steinepreis Paganin
Level 4, The Read Buildings
16 Milligan Street
Perth WA 6000

Auditor

BDO Audit (WA) Pty Ltd
38 Station Street
Subiaco WA 6008

When was the Company founded?

The Company was founded in June 2016.

How can I buy and sell shares?

Cannpal’s shares are traded on the ASX and can be bought or sold through a Licensed Stock Broker. The process of buying or selling shares is explained on the ASX website.

Where can I view the Company prospectus?

You can view the Cannpal prospectus here.

What is the Company's ASX code?

The Company’s ASX code is CP1

Where can I find information about my Shareholdings?

The CannPal share register is managed by Computershare Investor Services Pty Ltd (Computershare). Computershare provides a number of services which can be accessed online. When accessing some information online you may be required to enter your Security Reference Number (SRN) or Holder Identification Number (HIN) as shown on your Issuer Sponsored/CHESS statements and other personal details such as your postcode.

Please contact Computershare if you have any inquiries. It will assist if you can quote your current address together with your Security Reference Number (SRN) or Holder Identification Number (HIN) as shown on your Issuer Sponsored/CHESS statements.

Computershare Investor Services Pty Ltd

Telephone
Australia
: 1300 367 027
International: (+61 3) 9946 4421

Website
www.computershare.com.au

Postal address
The Registrar Computershare Investor Services Pty Ltd
GPO Box 2975
MELBOURNE VIC 3001

Office address
Level 11, 172 St George’s Terrace
PERTH WA 6000

Who can I contact about media inquiries?

Media enquiries

Julia Maguire

The Capital Network

M: +61 419 815 386

E: julia@thecapitalnetwork.com.au

Is Cannabis legal for animals?

The regulatory environment around cannabis for animals is still very unclear. In all major jurisdictions that we are aware of, medical cannabis for animals is illegal, unless it’s being used for medical research purposes and with the necessary permits.

How can I treat my animal with medical cannabis?

You should always seek professional advice from a veterinarian when treating animals for any illness. Unfortunately we cannot give you advice, but we are working towards having our products scientifically tested, validated and labelled correctly to inform and allow veterinarians to prescribe medical cannabis medications for animals.

When can I buy your products?

CannPal is working with regulatory authorities to validate the safety and efficacy of medical cannabis for use in companion pets. This is an arduous process and involves robust clinical studies that take time. This process in its entirety can take 3 to 4 years and in some cases more.

However medical cannabis is an evolving industry and while we will continue to complete the required safety and efficacy studies to show our products are safe and efficacious for regulatory authorities, we are following the legislative changes closely and should there be an opportunity to enter a legal market earlier than anticipated, we are well placed to do so.

We are also researching the benefits of CBD derived from hemp, which isn’t bound by the same legislative rules as medical cannabis. We hope to be able to market a product derived from the hemp plant as early 2019.

Is cannabis dangerous for pets?

Cannabis can be dangerous for animals when taken incorrectly. Dogs have more cannabinoid receptors than humans and can be very sensitive to THC, the psychoactive cannabinoid in cannabis. If you suspect your dog has consumed marijuana without your supervision, take them to the vet immediately. The following signs indicate that your dog may have consumer too much cannabis:

  • Dribbling urine
  • Walking like they’re intoxicated
  • Beginning to fall over while standing still
  • Low heart rate
  • Low blood pressure
  • Wide, dilated pupils
  • Easily startled by sudden sounds

However when consumed in the correct ratios of cannabinoids and dosages, and under medical supervision, cannabis is a wonderful medicine for a range of ailments and we’re working to be able to provide pet owners with safe, standardised and dosage controlled medicines using cannabis.

Where can I view the Company's corporate governance plan?

You can view all the Company’s policies and the corporate governance plan here

2018

Date Document
19/06/2018 Non-deal Roadshow Presentation
18/06/2018 Market Update on Studies
29/05/2018 CannPal Enters into Manufacturing Agreement with JayChem
23/04/2018 Appendix 4C - Quarterly 31 March 2018
27/03/2018 CannPal Imports Cannabis Oils for Clinical Trial
06/03/2018 Appendix 3B
27/02/2018 CannPal Further Bolsters its Research Team
20/02/2018 Half Yearly Report and Accounts 31 December 2017
19/02/2018 Escrow Share Release 2 March 2018
31/01/2018 Appendix 4C - Quarterly Cash Flow Report
08/01/2018 Corrected Appendix 3B

2017

Date Document
18/12/2017 CannPal Granted SME Status by the European Medicines Agency
12/12/2017 Investor Presentation
08/12/2017 Change of Director's Interest Notice L Mills
08/12/2017 Appendix 3B
07/12/2017 CannPal Receives Import Consent from APVMA
22/11/2017 CannPal Granted Licence to Import from the ODC
10/11/2017 CannPal Appoints Head of Clinical Development and R&D
01/11/2017 CannPal Authorisation to Possess & Supply Medical Cannabis
31/10/2017 Appendix 4C - Quarterly 30 September 2017
30/10/2017 CannPal enters Research Agreement with Queensland University
27/10/2017 Substantial holder notice
27/10/2017 Substantial holder notice
25/10/2017 Substantial holder notice
25/10/2017 Substantial holder notice
25/10/2017 Initial Director's Interest Notice K Adams
25/10/2017 Initial Director's Interest Notice R Clifford
25/10/2017 Initial Director's Interest Notice L Mills
25/10/2017 Initial Director's Interest Notice RM Johnston
25/10/2017 Initial Director's Interest Notice G Starr
25/10/2017 CP1 Ethics Approval
25/10/2017 CP1 ASX Listing Announcement
23/10/2017 Statement of Confirmations
23/10/2017 Corporate Governance Statement
23/10/2017 Securities Trading Policy
23/10/2017 Employee Incentive Option Plan
23/10/2017 Intellectual Property Report
23/10/2017 Audited accounts for year ended 30 June 2017
23/10/2017 Constitution
23/10/2017 Prospectus
23/10/2017 Appendix 1A and Information Form & Checklist
23/10/2017 Top 20 Holders
23/10/2017 Distribution Schedule
23/10/2017 Pre-quotation Disclosure
23/10/2017 ASX Notice
23/10/2017 Admission to Official Quotation

29/08/2017

Zelda Therapeutics Ltd’s Dr. Stewart Washer discusses medical cannabis achievements

29/08/2017

More firms target medical cannabis space

30/08/2017

Sydney startup CannPal prepares for ASX listing in mission to ease pet pain with medical cannabis

31/08/2017

Cannabis startup CannPal to list on ASX, targets $4.7m IPO

31/08/2017

Australian pot stocks: August update

04/09/2017

CannPal to take medical cannabis for pets onto the ASX

25/10/2017

Pot stock Cannpal Animal Therapeutics Ltd hits the ASX boards

05/09/2017

Treat your companion animal’s anxiety with medicinal cannabis

06/09/2017

Investors get tutorial on medical pet cannabis via CannPal float

15/09/2017

CannPal Prepares To Bring Pots to Pets

18/09/2017

CannPal is developing Pot that brings pain relief to distressed pets

18/09/2017

CannPal Animal Therapeutics

02/11/2017

CannPal Animal Therapeutics granted medical cannabis permit

24/11/2017

CannPal trials to go ahead following import licence

18/12/17

European boost for Australian cannabis treatment firm

03/01/18

Why Aussie pot stocks are smoking the market today

10/01/18

Investors rush to take advantage of pot stock high

19/01/18

Turning a new leaf: 5 medical cannabis trends for 2018

27/02/18

CannPal adds ex-Elanco toxicology expert to research team

07/02/18

Medicinal cannabis shares are smoking the market

28/03/18

CannPal trial to begin following first imports of cannabis formulations

21/03/18

Bill seeks medical cannabis access for pets in New York

27/03/18

Australian company set to begin MMJ for dogs study

27/03/18

CannPal primed to test flagship cannabis pain relief drug for animals 

27/03/18

CannPal imports first medical cannabis

02/04/18

CannPal Canine Cannabis Clinical Trial to Commence This Week

05/04/18

Australian medicinal cannabis industry Q1 update